Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2191 - AMALTHEA: A prospective, single-arm study of the Hellenic Cooperative Oncology Group evaluating the efficacy and safety of 1st line FOLFIRI+Aflibercept in patients with metastatic colorectal cancer.

Date

09 Sep 2017

Session

Poster display session

Presenters

George Pentheroudakis

Citation

Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393

Authors

G. Pentheroudakis1, V. Kotoula1, G. Koliou1, I. Tikas1, V. Karavasilis1, E. Samantas1, G. Aravantinos1, E. Daskalaki1, I. Souglakos2, G. Koumakis1, I. Efstratiou1, C. Petraki1, C. Poulios1, D. Bafaloukos1, D. Pectasides1, E. Vrettou1, G. Fountzilas1

Author affiliations

  • 1 Data Office, Hellenic Cooperative Oncology Group (HeCOG), 11524 - Athens/GR
  • 2 Division Of Internal Medicine, University of Crete, Heraklion/GR
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2191

Background

The efficacy and safety of the FOLFIRI regimen combined with aflibercept has not been studied in the first-line management of patients with metastatic colorectal cancer (mCRC).

Methods

In the context of a prospective single-arm trial, patients with mCRC received standard doses of Leucovorin, 5-Fluorouracil and Irinotecan (FOLFIRI) combined with aflibercept (4 mg/KBW iv) every 2 weeks until disease progression, unacceptable toxicity or completion of 12 cycles, followed by aflibercept maintenance. Endpoints were the 12-month Progression-Free Rate (PFR12), efficacy and toxicity.

Results

73 fit patients were enrolled in the study between 2014 and 2016. Fifty-five patients had tumors in the left colon, forty-four presented with synchronous metastases. Median relative dose intensities administered were 0.85 (95% CI 0.74-0.84) for 5-FU CI, 0.80 (95% CI 0.73-0.89) for Irinotecan and 1.0 (95% CI 0.92-0.98) for Aflibercept. In total, adverse events occurred in 70 patients (95.9%), with no toxic deaths. The most common grade 3 or 4 adverse events were neutropenia (13 patients, 18%), febrile neutropenia (3 patients, 4%), diarrhoea (11 patients, 15%), hypertension (19 pts, 26%), proteinuria (8 pts, 11%), infections (8 pts, 11%), mucositis (6 pts, 8%). Among 85 adverse events of special interest (AESI) observed, 57 events ended with complete recovery. Among eight patients with severe proteinuria, improvement to grade 0/2 occurred in six at a median time of 4.8 months. The Objective Response Rate (ORR) was 46.6% in the ITT population (n = 73) and 51.5% in the evaluable population (n = 66). Among potential prognostic clinicopathological parameters (including RAS, BRAF status, primary site), the presence of synchronous metastases and a relapse-free interval

Conclusions

The FOLFIRI + Aflibercept regimen is active and safe, however it failed to improve historical benchmarks of efficacy in chemonaive patients with mCRC.

Clinical trial identification

EudraCT No.: 2013-002567-26

Legal entity responsible for the study

Hellenic Cooperative Oncology Group (HeCOG)

Funding

Sanofi-Aventis

Disclosure

V. Karavasilis: Advisory Board: Novartis, Roche, Astellas, Merck, Sanofi, Pfizer, Astra-Zeneca, Janssen. Honoraria: Novartis, Roche, Astellas, Merck, Sanofi, Pfizer, Astra-Zeneca, Janssen. G. Aravantinos: Honoraria: Genesis pharma SA Scientific Advisory Board: Amgen, Astra-Zeneca, BMS, GSK, Roche, Sanofi. I. Souglakos: Honoraria: Sanofi. Research grant: Sanofi. G. Fountzilas: Honoraria: Astra-Zeneca. Consulting or Advisory Role: Pfizer, Sanofi, Roche. Stock and other ownership interests (an Immediate family member): Ariad. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.